Outcome

The study provides compelling evidence that Hyperbaric Oxygen Therapy (HBOT) can significantly benefit individuals suffering from long COVID-19 by reducing systemic inflammation and oxidative stress. By administering 100% inspired oxygen at 2.4 ATA the research showed notable improvements across various markers such as attenuated reactive oxygen species (ROS) production reduced lipid peroxidation decreased DNA damage lower nitric oxide (NO) metabolite levels and diminished inflammation biomarkers.

Introduction

Long COVID-19 has been affecting many people including professional athletes with debilitating symptoms such as fatigue and systemic inflammation. This study explores the potential of hyperbaric oxygen therapy (HBOT) to mitigate these chronic symptoms. HBOT by enhancing oxygenation may help reduce inflammation and improve overall health. The study involved five subjects: three athletes undergoing 15 HBOT sessions over three weeks two patients with idiopathic sudden sensorineural hearing loss completing 30 sessions over six weeks and one patient with osteomyelitis following a similar regimen plus additional treatment. Researchers measured various biomarkers such as reactive oxygen species (ROS) lipid peroxidation and DNA damage before and after the treatment. Notably the athletes showed significant improvement post-treatment with reduced ROS production lipid peroxidation and inflammation biomarkers. These promising results suggest that HBOT could offer an effective non-invasive method for alleviating long COVID-19 symptoms.

Results

The study evaluated the impact of Hyperbaric Oxygen Therapy (HBOT) on long COVID-19 sufferers including professional athletes and individuals with other chronic conditions. The cohort consisted of three athletes undergoing 15 HBOT sessions over three weeks two patients with idiopathic sudden sensorineural hearing loss completing 30 sessions over six weeks and one patient with osteomyelitis following a regimen of 30 HBOT sessions followed by a 30-day break and an additional cycle of 20 sessions.

HBOT treatment involved administering 100% inspired oxygen at 2.4 atmospheres absolute (ATA) for 90 minutes per session. Researchers assessed the treatment’s effectiveness by measuring biomarkers of oxidative stress and inflammation in saliva and urine samples before and after therapy.

Findings revealed significant improvements across a variety of biomarkers:

• Reduction in Reactive Oxygen Species (ROS): A marked decrease in ROS production was observed indicating lowered oxidative stress levels post-HBOT.
• Lipid Peroxidation: There was a significant reduction in the lipid peroxidation process which is frequently associated with cell damage due to oxidative stress.
• DNA Damage: The study noted lower levels of DNA damage showcasing the potential protective effects of HBOT at a cellular level.
• Nitric Oxide (NO) Metabolites: Decreased levels of NO metabolites were recorded which are often linked to inflammatory processes.
• Inflammation Biomarkers: There was a notable decrease in inflammation biomarkers suggesting an overall reduction in systemic inflammation.

These beneficial effects were particularly pronounced among the athletes who demonstrated significant improvements post-treatment. The study suggests that HBOT effectively counteracts oxidative stress and inflammation-driven symptoms in long COVID-19 patients proposing a viable non-invasive therapeutic option to alleviate persistent symptoms associated with the condition. Additionally similar positive outcomes were observed in patients with idiopathic sudden sensorineural hearing loss and osteomyelitis although they required longer treatment protocols.

Overall the results substantiate the potential of HBOT to significantly improve health outcomes for individuals suffering from the lingering effects of long COVID-19 and other chronic conditions highlighting its role in enhancing patients’ quality of life.

Conclusion

In summary this study demonstrates that Hyperbaric Oxygen Therapy (HBOT) significantly alleviates inflammation and oxidative stress in individuals suffering from long COVID-19 particularly athletes. By enhancing oxygenation HBOT effectively reduces levels of reactive oxygen species (ROS) lipid peroxidation DNA damage nitric oxide (NO) metabolites and inflammation biomarkers. These findings underscore the potential of HBOT as a non-invasive and effective treatment for persistent symptoms associated with long COVID-19. Given the promising improvement observed in athletes and other patients with chronic conditions such as idiopathic sudden sensorineural hearing loss and osteomyelitis further research is warranted. Future studies should explore optimal treatment protocols long-term effects and the potential application of HBOT in broader clinical settings to establish its role in managing post-COVID inflammatory states and enhancing patient quality of life.